A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial

Yolanda de Diego-Otero, Rocio Calvo-Medina, Carolina Quintero-Navarro, Lourdes Sánchez-Salido, Francisco García-Guirado, Ignacio del Arco-Herrera, Isabel Fernández-Carvajal, Teresa Ferrando-Lucas, Rafaela Caballero-Andaluz, Lucia Pérez-Costillas, Yolanda de Diego-Otero, Rocio Calvo-Medina, Carolina Quintero-Navarro, Lourdes Sánchez-Salido, Francisco García-Guirado, Ignacio del Arco-Herrera, Isabel Fernández-Carvajal, Teresa Ferrando-Lucas, Rafaela Caballero-Andaluz, Lucia Pérez-Costillas

Abstract

Background: Fragile X syndrome (FXS) is an inherited neurodevelopmental condition characterised by behavioural, learning disabilities, physical and neurological symptoms. In addition, an important degree of comorbidity with autism is also present. Considered a rare disorder affecting both genders, it first becomes apparent during childhood with displays of language delay and behavioural symptoms.Main aim: To show whether the combination of 10 mg/kg/day of ascorbic acid (vitamin C) and 10 mg/kg/day of α-tocopherol (vitamin E) reduces FXS symptoms among male patients ages 6 to 18 years compared to placebo treatment, as measured on the standardized rating scales at baseline, and after 12 and 24 weeks of treatment.Secondary aims: To assess the safety of the treatment. To describe behavioural and cognitive changes revealed by the Developmental Behaviour Checklist Short Form (DBC-P24) and the Wechsler Intelligence Scale for Children-Revised. To describe metabolic changes revealed by blood analysis. To measure treatment impact at home and in an academic environment.

Methods/design: A phase II randomized, double-blind pilot clinical trial.

Scope: male children and adolescents diagnosed with FXS, in accordance with a standardized molecular biology test, who met all the inclusion criteria and none of the exclusion criteria.

Instrumentation: clinical data, blood analysis, Wechsler Intelligence Scale for Children-Revised, Conners parent and teacher rating scale scores and the DBC-P24 results will be obtained at the baseline (t0). Follow up examinations will take place at 12 weeks (t1) and 24 weeks (t2) of treatment.

Discussion: A limited number of clinical trials have been carried out on children with FXS, but more are necessary as current treatment possibilities are insufficient and often provoke side effects. In the present study, we sought to overcome possible methodological problems by conducting a phase II pilot study in order to calculate the relevant statistical parameters and determine the safety of the proposed treatment. The results will provide evidence to improve hyperactivity control and reduce behavioural and learning problems using ascorbic acid (vitamin C) and α-tocopherol (vitamin E). The study protocol was approved by the Regional Government Committee for Clinical Trials in Andalusia and the Spanish agency for drugs and health products.

Trial registration: ClinicalTrials.gov Identifier: NCT01329770 (29 March 2011).

Figures

Figure 1
Figure 1
Clinical trial flowchart.
Figure 2
Figure 2
Randomization criteria for the trial. Randomization by blocks and stratification for confusion factors (age and concomitant medication). T: Treated group, C: Control group.

References

    1. Martin JP, Bell J. A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry. 1943;6:154–157. doi: 10.1136/jnnp.6.3-4.154.
    1. Sutherland GR, Ashford PL. X-linked mental retardation with macro-orchidism and the fragile site at Xq 27 or 28. Hum Genet. 1979;48:117–120. doi: 10.1007/BF00273283.
    1. Chakrabarti L, Davies KE. Fragile X syndrome. Curr Opin Neurol. 1997;10:142–147. doi: 10.1097/00019052-199704000-00012.
    1. Sherman SL. Genetic epidemiology of the fragile X syndrome with special reference to genetic counseling. Prog Clin Biol Res. 1991;368:79–99.
    1. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009;11:324–329. doi: 10.2353/jmoldx.2009.080173.
    1. Rifé M, Badenas C, Mallolas J, Jiménez L, Cervera R, Maya A, Glover G, Rivera F, Milà M. Incidence of fragile X in 5,000 consecutive newborn males. Genet Test. 2003;7:339–343. doi: 10.1089/109065703322783725.
    1. De Vries BB, Mohkamsing S, van den Ouweland AM, Duivenvoorden HJ, Mol E, Gelsema K, van Rijn M, Halley DJ, Sandkuijl LA, Oostra BA, Tibben A, Niermeijer MF, Collaborative Fragile X Study Group Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Am J Hum Genet. 1997;61:660–667. doi: 10.1086/515496.
    1. Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, editors. Fragile X Syndrome: Diagnosis, Treatment, and Research. 3. Baltimore: Johns Hopkins University Press; 2002. pp. 3–109.
    1. Hoeft F, Carter JC, Lightbody AA, Cody Hazlett H, Piven J, Reiss AL. Region-specific alterations in brain development in one- to three-year-old boys with fragile X syndrome. Proc Natl Acad Sci U S A. 2010;107:9335–9339. doi: 10.1073/pnas.1002762107.
    1. Schapiro MB, Murphy DGM, Hagerman RJ, Azari NP, Alexander GE, Miezejeski CM, Hinton VJ, Horwitz B, Haxby JV, Kumar A, White B, Grady CL. Adult fragile X syndrome: neuropsychology, brain anatomy, and metabolism. Am J Med Genet. 1995;60:480–493. doi: 10.1002/ajmg.1320600603.
    1. Lubs H. A marker X chromosome. Am J Hum Genet. 1969;21:231–244.
    1. Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DPA, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, Eussen BE, van Ommen GJB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65:905–914. doi: 10.1016/0092-8674(91)90397-H.
    1. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkert AJ, Holden JJ, Fenwick RG, Jr, Warren ST, Oostra BA, Nelson DL, Caskey CT. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell. 1991;67:1047–1058. doi: 10.1016/0092-8674(91)90283-5.
    1. Hessl D, Tassone F, Loesch DZ, Berry-Kravis E, Leehey MA, Gane LW, Barbato I, Rice C, Gould E, Hall DA, Grigsby J, Wegelin JA, Harris S, Lewin F, Weinberg D, Hagerman PJ, Hagerman RJ. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet. 2005;139B:115–121. doi: 10.1002/ajmg.b.30241.
    1. Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, Brunberg JA, Greco C, Des Portes V, Jardini T, Levine R, Berry-Kravis E, Brown WT, Schaeffer S, Kissel J, Tassone F, Hagerman PJ. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003;72:869–878. doi: 10.1086/374321.
    1. De Diego OY, Severijnen LA, van Cappellen G, Schrier M, Oostra B, Willemsen R. Microtubule-mediated transport of FMR1-protein via granules in neurites of PC12 cells. Mol Cel Biol. 2002;22:8332–8341. doi: 10.1128/MCB.22.23.8332-8341.2002.
    1. de Diego OY, Bakker CE, Raghoe P, Severijnen LAWFM, Hoogeveen A, Oostra BA, Willemsen R. Immunocytochemical characterization of FMRP, FXR1P and FXR2P during embryonic development in the mouse. Gene Funct Dis. 2000;1:28–37. doi: 10.1002/1438-826X(200005)1:1<28::AID-GNFD28>;2-F.
    1. Hessl D, Glaser B, Dyer-Friedman J, Reiss AL. Social behavior and cortisol reactivity in children with fragile X syndrome. J Child Psychol Psychiatry. 2006;47:602–610. doi: 10.1111/j.1469-7610.2005.01556.x.
    1. Hessl D, Rivera SM, Reiss AL. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment Retard Dev Disabil Res Rev. 2004;10:17–24. doi: 10.1002/mrdd.20004.
    1. Markham JA, Beckel-Mitchener AC, Estrada CM, Greenough WT. Corticosterone response to acute stress in a mouse model of fragile X syndrome. Psychoneuroendocrinology. 2006;31:781–785. doi: 10.1016/j.psyneuen.2006.02.008.
    1. de Diego-Otero Y, Romero-Zerbo Y, el Bekay R, Decara J, Sanchez L, Rodriguez-de Fonseca F, del Arco-Herrera I. α-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology. 2009;34:1011–1026. doi: 10.1038/npp.2008.152.
    1. el Bekay R, Romero-Zerbo Y, Decara J, Sanchez-Salido L, Del Arco-Herrera I, Rodríguez-de Fonseca F, de Diego-Otero Y. Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from fragile X mental retardation 1-deficient mice, a pathological model for fragile X syndrome. Eur J Neurosci. 2007;26:3169–3180. doi: 10.1111/j.1460-9568.2007.05939.x.
    1. Steullet P, Cabungcal JH, Kulak A, Kraftsik R, Chen Y, Dalton TP, Cuenod M, Do KQ. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, γ oscillations, and related behaviors. J Neurosci. 2010;30:2547–2558. doi: 10.1523/JNEUROSCI.3857-09.2010.
    1. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol. 1992;31:119–130. doi: 10.1002/ana.410310202.
    1. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179–185. doi: 10.1016/0092-8674(95)90401-8.
    1. Rosen LB, Ginty DD, Weber MJ, Greenberg ME. Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron. 1994;12:1207–1221. doi: 10.1016/0896-6273(94)90438-3.
    1. Kishida KT, Klann E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid Redox Signal. 2007;9(2):233–244. doi: 10.1089/ars.2007.9.233.
    1. Janaky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yoneda Y, Shaw CA. Glutathione and signal transduction in the mammalian CNS. J Neurochem. 1999;73:889–902. doi: 10.1046/j.1471-4159.1999.0730889.x.
    1. Rauhala P, Lin AMY, Chiueh CC. Neuroprotection by S-nitrosoglutathione of brain dopamine neurons from oxidative stress. FASEB J. 1998;12:165–173.
    1. Poot M, Teubert H, Rabinovitch PS, Kavanagh TJ. De novo synthesis of glutathione is required for both entry into and progression through the cell cycle. J Cell Physiol. 1995;163:555–560. doi: 10.1002/jcp.1041630316.
    1. Aoyama K, Watabe M, Nakaki T. Regulation of neuronal glutathione synthesis. J Pharmacol Sci. 2008;108:227–238. doi: 10.1254/jphs.08R01CR.
    1. Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer’s disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal. 2006;8:2021–2037. doi: 10.1089/ars.2006.8.2021.
    1. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ, for the Members of the Disease Cooperative Study A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med. 1997;336:1216–1222. doi: 10.1056/NEJM199704243361704.
    1. Di Matteo V, Esposito E. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Curr Drug Target CNS Neurol Disord. 2003;2:95–107. doi: 10.2174/1568007033482959.
    1. Riga S, Riga D. An antistress and antiaging neurometabolic therapy: accelerated lipofuscinolysis and stimulated anabolic regeneration by the antagonic-stress synergistic formula. Ann N Y Acad Sci. 1995;771:535–550. doi: 10.1111/j.1749-6632.1995.tb44708.x.
    1. Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome present and future. Ment Retard Dev Disabil Res Rev. 2004;10:42–48. doi: 10.1002/mrdd.20007.
    1. Bradford A, Atkinson J, Fuller N, Rand RP. The effect of vitamin E on the structure of membrane lipid assemblies. J Lipid Res. 2003;44:1940–1945. doi: 10.1194/jlr.M300146-JLR200.
    1. Azzi A, Ricciarelli R, Zingg JM. Non-antioxidant molecular functions of α-tocopherol (vitamin E) FEBS Lett. 2002;519:8–10. doi: 10.1016/S0014-5793(02)02706-0.
    1. Azzi A, Breyer I, Feher M, Pastori M, Ricciarelli R, Spycher S, Staffieri M, Stocker A, Zimmer S, Zingg JM. Specific cellular responses to α-tocopherol. J Nutr. 2000;130:1649–1652.
    1. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI. Free fatty acid-induced insulin resistance is associated with activation of protein kinase Cθ and alterations in the insulin signaling cascade. Diabetes. 1999;48:1270–1274. doi: 10.2337/diabetes.48.6.1270.
    1. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 14. Hudson, OH: Lexi-Comp; 2007.
    1. Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr. 1999;135:601–610. doi: 10.1016/S0022-3476(99)70059-4.
    1. Winklhofer-Roob BM, van’t Hof MA, Shmerling DH. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-α-tocopherol compared with all-rac-α-tocopheryl acetate preparations. Am J Clin Nutr. 1996;63:722–728.
    1. Wilfond BS, Farrell PM, Laxova A, Mischler E. Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis. Clin Pediatr. 1994;33:2–7. doi: 10.1177/000992289403300101.
    1. Brigelius-Flohé R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM, Azzi A. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr. 2002;76:703–716.
    1. Moyano D, Vilaseca MA, Pineda M, Campistol J, Vernet A, Póo P, Artuch R, Sierra C. Tocopherol in inborn errors of intermediary metabolism. Clin Chim Acta. 1997;263:147–155. doi: 10.1016/S0009-8981(97)00061-2.
    1. Shirakata Y, Shiraishi S, Sayama K, Shinmori H, Miki Y. High-dose tocopherol acetate therapy in epidermolysis bullosa siblings of the Cockayne-Touraine type. J Dermatol. 1993;20:723–725.
    1. Eldamhoughy S, Elhelw Z, Yamamah G, Hussein L, Fayyad I, Fawzy D. The vitamin E status among glucose-6 phosphate dehydrogenase deficient patients and effectiveness of oral vitamin E. Int J Vitam Nutr Res. 1988;58:184–188.
    1. Tahzib M, Frank R, Gauthier B, Valderrama E, Trachtman H. Vitamin E treatment of focal segmental glomerulosclerosis: results of an open-label study. Pediatr Nephrol. 1999;13:649–652. doi: 10.1007/s004670050674.
    1. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734–738. doi: 10.1016/S0022-3476(00)05040-X.
    1. Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, Capuano G, Migliaro F. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004;38:48–55. doi: 10.1097/00005176-200401000-00012.
    1. Yasui K, Kurata T, Yashiro M, Tsuge M, Ohtsuki S, Morishima T. The effect of ascorbate on minor recurrent aphthous stomatitis. Acta Paediatr. 2010;99:442–445. doi: 10.1111/j.1651-2227.2009.01628.x.
    1. Barbosa E, Faintuch J, Machado Moreira EA, da Silva VR G, Lopes Pereima MJ, Martins Fagundes RL, Filho DW. Supplementation of vitamin E, vitamin C, and zinc attenuates oxidative stress in burned children: a randomized, double-blind, placebo-controlled pilot study. J Burn Care Res. 2009;30:859–866. doi: 10.1097/BCR.0b013e3181b487a8.
    1. Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, Stuehlinger M, Lin KY, Cooke JP, Morrow JD, Ridker PM, Rifai N, Miller E, Witztum JL, Mietus-Snyder M. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 2003;108:1059–1063. doi: 10.1161/01.CIR.0000086345.09861.A0.
    1. Burns J, Ouvrier RA, Yiu EM, Joseph PD, Kornberg AJ, Fahey MC, Ryan MM. Ascorbic acid for Charcot–Marie–Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol. 2009;8:537–544. doi: 10.1016/S1474-4422(09)70108-5.
    1. Chan AC. Partners in defense, vitamin E and vitamin C. Can J Physiol Pharmacol. 1993;71:25–31.
    1. Conners CK, Sitarenios G, Parker JDA, Epstein JN. The revised Conners’ Parent Rating Scale (CPRS–R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26:257–268. doi: 10.1023/A:1022602400621.
    1. Conners CK, Sitarenios G, Parker JDA, Epstein JN. Revision and restandardization of the Conners Teacher Rating Scale (CTRS–R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26:279–291. doi: 10.1023/A:1022606501530.
    1. Farré-Riba A, Narbona J. [Conners’ rating scales in the assessment of attention deficit disorder with hyperactivity (ADHD): a new validation and factor analysis in Spanish children] [Article in Spanish] Rev Neurol. 1997;25:200–204.
    1. Taffe JR, Gray KM, Einfeld SL, Dekker MC, Koot HM, Emerson E, Koskentausta T, Tonge BJ. Short form of the Developmental Behaviour Checklist. Am J Ment Retard. 2007;112:31–39. doi: 10.1352/0895-8017(2007)112[31:SFOTDB];2.
    1. Badia X, Gutiérrez F, Wiklund I, Alonso J. Validity and reliability of the Spanish version of the Psychological General Well-Being Index. Qual Life Res. 1996;5:101–108. doi: 10.1007/BF00435974.
    1. Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, Ufer M, Des Portes V, Gomez-Mancilla B. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014;231:1237–1250. doi: 10.1007/s00213-013-3289-0.
    1. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4:152ra127. doi: 10.1126/scitranslmed.3004214.
    1. de Esch CEF, Zeidler S, Willemsen R: Translational endpoints in fragile X syndrome.Neurosci Biobehav Rev in press. doi:10.1016/j.neubiorev.2013.10.012
    1. Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr. 2013;34:147–155. doi: 10.1097/DBP.0b013e318287cd17.
    1. Erickson CA, Weng N, Weiler IJ, Greenough WT, Stigler KA, Wink LK, McDougle CJ. Open-label riluzole in fragile X syndrome. Brain Res. 2011;1380:264–270. doi: 10.1016/j.brainres.2010.10.108.
    1. Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012;37:509–518. doi: 10.1016/j.psyneuen.2011.07.020.
    1. Sahu JK, Gulati S, Sapra S, Arya R, Chauhan S, Chowdhury MR, Gupta N, Kabra M, Gupta YK, Dwivedi SN, Kalra V. Effectiveness and safety of donepezil in boys with fragile X syndrome: a double-blind, randomized, controlled pilot study. J Child Neurol. 2013;28:570–575. doi: 10.1177/0883073812449381.
    1. Chen E, Sharma MR, Shi X, Agrawal RK, Joseph S. Fragile X mental retardation protein regulates translation by binding directly to the ribosome. Mol Cell. 2014;54:407–417. doi: 10.1016/j.molcel.2014.03.023.
    1. Brown WT, Jenkins EC, Friedman E, Brooks J, Cohen IL, Duncan C, Hill AL, Malik MN, Morris V, Wolf E, Wisniewski K, French JH, Opitz JM. Folic acid therapy in the fragile X syndrome. Am J Med Genet. 1984;17:289–297. doi: 10.1002/ajmg.1320170121.
    1. Carpenter NJ, Barber DH, Jones M, Lindley W, Carr C. Controlled six-month study of oral folic acid therapy in boys with fragile X-linked mental retardation. Am J Med Genet. 1983;35:82A.
    1. Fisch GS, Cohen IL, Gross AC, Jenkins V, Jenkins EC, Brown WT. Folic acid treatment of fragile X males: a further study. Am J Med Genet. 1988;30:393–399. doi: 10.1002/ajmg.1320300139.
    1. Strom CM, Brusca RM, Pizzi WJ. Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin) for the treatment of fragile X syndrome. Am J Med Genet. 1992;44:676–682. doi: 10.1002/ajmg.1320440529.
    1. Torrioli MG, Vernacotola S, Mariotti P, Bianchi E, Calvani M, De Gaetano A, Chiurazzi P, Neri G. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behaviour in fragile X syndrome. Am J Med Genet. 1999;87:366–368. doi: 10.1002/(SICI)1096-8628(19991203)87:4<366::AID-AJMG18>;2-F.
    1. Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, Marzullo E, Romeo G, Vallee L, Veneselli E, Cocchi E, Garbarino E, Moscato U, Chiurazzi P, D’Iddio S, Calvani M, Neri G. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008;146A:803–812. doi: 10.1002/ajmg.a.32268.
    1. Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, Decle P, Potanos K, Cook E, Salt J, Maino D, Weinberg D, Lara R, Jardini T, Cogswell J, Johnson SA, Hagerman R. Effect of CX516, an AMPA-modulating compound, on cognition and behaviour in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006;16:525–540. doi: 10.1089/cap.2006.16.525.
    1. Levy SL, Burnham WM, Bishai A, Hwang PA. The anticonvulsant effects of vitamin E: a further evaluation. Can J Neurol Sci. 1992;19:201–203.
    1. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, Hagerman R. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46:266–271. doi: 10.1136/jmg.2008.063701.
    1. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3:64ra1. doi: 10.1126/scitranslmed.3001708.
    1. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29:293–302. doi: 10.1097/DBP.0b013e31817dc447.
    1. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci. 2010;30:9929–9938. doi: 10.1523/JNEUROSCI.1714-10.2010.
    1. Torrioli M, Vernacotola S, Setini C, Bevilacqua F, Martinelli D, Snape M, Hutchison JA, Di Raimo FR, Tabolacci E, Neri G. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A. 2010;152A:1420–1427.
    1. Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, Goodlin-Jones BL. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5:145–150.
    1. Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SM, Ethell IM, Nguyen DV. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil. 2010;115:433–443. doi: 10.1352/1944-7558-115.5.433.
    1. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010;10:91. doi: 10.1186/1471-2377-10-91.
    1. Erickson CA, Mullett JE, McDougle CJ. Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord. 2010;40:1412–1416. doi: 10.1007/s10803-010-0988-9.
    1. Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, McDougle CJ. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology (Berl) 2011;216:85–90. doi: 10.1007/s00213-011-2194-7.
    1. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons; 2008. p. 16.
    1. Kappus H, Diplock AT. Tolerance and safety of vitamin E: a toxicological position report. Free Radic Biol Med. 1992;13:55–74. doi: 10.1016/0891-5849(92)90166-E.
    1. Ogunmekan AO, Hwang PA. A randomized, double-blind, placebo-controlled, clinical trial of D-α-tocopheryl acetate (vitamin E), as add-on therapy, for epilepsy in children. Epilepsia. 1989;30:84–89. doi: 10.1111/j.1528-1157.1989.tb05287.x.
    1. Papas KA, Sontag MK, Pardee C, Sokol RJ, Sagel SD, Accurso FJ, Wagener JS. A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. J Cyst Fibros. 2008;7:60–67. doi: 10.1016/j.jcf.2007.05.001.
    1. Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1553–1561. doi: 10.1111/j.1365-2036.2006.03161.x.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera